NIAID’s Universal Flu Vaccine Candidate Advances to Second TrialÂ
In a phase 1 clinical trial, the vaccine developed by NIAID's Vaccine Research Center was safe, well-tolerated, and induced broad antibody responses that target the hemagglutinin stem.Â